RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on January 18, 2005 issued a press release titled "Ranbaxy 2004 full year sales up 21% at USD 1178 Mn; R&D expenses grow 41%; PAT- marginal growth to USD 164 Mn.". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the BODs at its meeting held on January 18,2005, has approved the appointment of Mr. Ramesh L Adige-Vice President(Corporate Affairs) as Whole-time Director of the Company effective January 18,2005.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K. Patawari, Company Secretary has been allotted 368 equity shares of the company on January 10, 2005 on exercise of stock options as per Employees Stock Option Scheme of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has on January 10, 2005, announced that the Company has so far made three filings of its Anti-Retrovirals (ARVs), to the USFDA for its approval under the expedited review process of the US Presidents Emergency Plan for AIDS Relief (PEPFAR). The details of the press release titled 'Ranbaxy HIV update - January 2005' shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on January 10, 2005, has allotted 93,068 Equity Shares on exercise of stock options under the Employees Stock Options Scheme of the Company. The paid-up Equity Share Capital of the Company post allotment will be Rs.1859838100.

Ranbaxy Laboratories Ltd has informed the Exchange that the company has issued a Press Release on December 23, 2004 titled "RANBAXY CONFERRED FIVE STAR EXPORT HOUSE STATUS BY DGFT. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 21, 2004 issued a press release titled 'Ranbaxy receives US FDA approval to market Fosinopril Sodium and Hydrochlorothiazide tablets'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 17, 2004 issued a Press release titled 'Ranbaxy receives tentative US FDA approval to market Topiramate tablets'. The details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 16, 2004 issued a press release titled "Ranbaxy Announces the Launch of Quinapril Tablets by Teva, Based on an Agreement between Ranbaxy and Teva." The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 15, 2004 issued a press release titled "RANBAXY GAINS US FDA APPROVAL FOR FLUOXETINE 40MG CAPSULES". The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 13, 2004 issued a press release titled "Ranbaxy receives tentative approval for Gabapentin Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on December 09, 2004 issued a press release titled "Ranbaxy Fine Chemicals Ltd. awarded ISO 14001:1996 Certification - First Indian laboratory chemical entity to achieve distinction". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on November 29,2004 issued a press release titled "UK Court judgement paves way for launch of Clarithromycin by Ranbaxy.- Abott's patent claims for solvent free drug held invalid.".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on November 22, 2004 issued a press release titled "RANBAXY LAUNCHES FLOTRAL FOR UROLOGICAL DISORDER AMONGST AGEING MALES-SAFE AND CONVENIENT TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA". The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the following is with reference to the news item which appeared in Bloomberg/Hindu Business Line dated November 15/16, 2004. The news relates to a matter which emanated in June 2004 and is not a new development. Ranbaxy (UK) Limited (RUKL), along with four other pharmaceutical companies in UK, have been served a notice of claim by the National Health Service, UK, over the alleged anti-competitive behaviour, with respect to the generic drug, Ranitidine. The Company has stated that the company is not aware of any wrong-doing and will contin

Ranbaxy Laboratories Ltd has informed the Exchange that they have been informed by Schwarz Pharma that the Phase II Clinical Trials of the molecule, RBx 2258 - Pamirosin (SPM 969) for Benign Prostate Hyperplasia (BPH), outlicensed by Ranbaxy to Schwarz Pharma, has been discontinued by them due to unclear preclinical findings. Until final resolution, the development programme has been put on hold by Schwarz.

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on October 29, 2004 issued a press release titled "Ranbaxy announced filing of ANDA application for Anti-Retroviral Agent." The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that The Calcutta Stock Exchange Association Limited vide their letter dated October 25, 2004 has informed the Company that their request for voluntary delisting of the securities of the Company has been approved by the Exchange on September 30, 2004 and that Notice for delisting is being issued by the Exchange. However, the securities of the Company will be traded under the 'Permitted Category' on the Exchange.

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on October 25, 2004 issued a press release titled "RANBAXY RECEIVES TENTATIVE APPROVAL FOR CARVEDILOL TABLETS". The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K. Patawari, Company Secretary has been allotted 1125 equity shares of the company on October 11, 2004 on exercise of stock options as per Employees Stock Option Scheme of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange that the BoD's at its meeting held on October 15, 2004, has approved the payment of interim dividend @ Rs.5/- per share for the year ending December 31, 2004. Record date for determination of entitlement of the interim dividend has been fixed as October 30, 2004. Interim Dividend will be paid to the eligible shareholders on or before November 10, 2004.

Ranbaxy Laboratories Ltd has informed the Exchange that on October 13, 2004 the company has decided to discontinue all its Rofecoxib formulations with immediate effect from India. Rofecoxib is currently being marketed by Ranbaxy also in Peru, Myanmar and Jordan, where it has a small marketshare. The product is being discontinued in these countries as well. The Company's decision is in conformity with its firm committment to ethical business practices. Merck withdrew Vioxx (Rofecoxib) from the market at the end of Sep 2004. In quick response, Ranbaxy had earlier issued a statement, advisin

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 11, 2004 has allotted 59,602 Equity Shares on exercise of stock options under the Employees Stock Option Scheme of the Company. The paidup Equity Share Capital of the Company post allotment will be Rs.1858907420.

Ranbaxy Laboratories Ltd has informed the Exchange that following long term evaluation of Vioxx (Rofecoxib) in the treatment of patients with the risk of developing recurrent polyps, Merck & Co. (Merck) noted "an increased relative risk for cardiovascular events, beginning after 18 months of treatment in the patients taking Rofecoxib compared to those taking Placebo. The results for the first 18 months of this study did not show any increased risk of confirmed cardiovascular events on Rofecoxib." As a result of these findings Merck decided to withdraw Vioxx, on a voluntary basis. Further det

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 30, 2004 announced that they have received approval from the U. S. Food and Drug Administration to manufacture and market Clorazepate Dipotassium Tablets USP, 3.75 mg, 7.5 mg, and 15 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug, Tranxene� Tablets, 3.75 mg, 7.5 mg, and 15 mg, respectively, of Ovation Pharmaceuticals, Inc.. Total market sales for Clorazepat

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 27, 2004 announced that they have received approval from the U. S. Food and Drug Administration to manufacture and market Clarithromycin Tablets USP, 250 mg and 500 mg. The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Ranbaxy Laboratories Ltd has informed the Exchange that the company has on September 23, 2004 announced that Ranbaxy Laboratories Ltd has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended-release Tablets, 10 mg/240 mg (24-Hour Formulation). The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).